摘要:
This invention relates to purified HCV E1 peptides, immunogenic composition comprising purified HCV E1 peptides, and a diagnostic kit for detecting HCV E1-specific antibodies. The purified HCV E1 peptide has an amino acid selected from the group consisting of SEQ ID NO:3; SEQ ID NO:5; and SEQ ID NO:7.
摘要翻译:本发明涉及纯化的HCV E1肽,包含纯化的HCV E1肽的免疫原性组合物和用于检测HCV E1特异性抗体的诊断试剂盒。 纯化的HCV E1肽具有选自SEQ ID NO:3的氨基酸; SEQ ID NO:5; 和SEQ ID NO:7。
摘要:
This invention relates to human or murine monoclonal antibodies specific for a peptide sequence of HCV E1, fragments of said monoclonal antibodies, hybridomas producing said monoclonal antibodies, in vitro diagnostic methods for detecting HCV E1-specific antigens in a biological sample, and diagnostic kits for detecting HCV E1-specific antigens in a biological sample.
摘要:
This invention relates to oligonucleotides encoding HCV E1 peptides, labeled oligonucleotide probes, recombinant DNA molecules comprising HCV E1 nucleotides, plasmids, expression vectors, transformed hosts, analytical kits for detecting nucleotide sequences of hepatitis C virus, and process for preparing polypeptides.
摘要:
The use of the HIP/PAP protein or a protein derivative thereof for manufacturing a medicament for preventing or treating: a neonatal brain injury, which includes a neonatal brain injury caused by a brain hypoxia, an adult or child brain injury, which includes an adult or child brain injury caused by a brain hypoxia, an adult or child or neonatal traumatic brain injury, a cerebellar disease or disorder, and a disease involving a defect in the production or in the phosphorylation of Gap-43.
摘要:
This invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytcs, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding that HIP/PAP administration has no adverse effects in mammals. This invention concerns a pharmaceutical composition for stimulating liver regeneration in vivo including after chronic/acute liver failure, comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue (36) and ending at the amino acid residue (175) of sequence SEQ ID No 1, in combination with at least one physiologically acceptable excipient.
摘要:
The invention relates to oligonucleotide sequences (or initiators) derived from the HIV-2 ROD virus genome and from that of the SIV-mac 142 virus, as well as their use in an in vitro method for the diagnosis of the infection of an individual by a HIV-2 type virus.
摘要:
The invention is directed generally to a DNA sequence coding for human cyclin A and in particular to antibodies, or antisera including such antibodies, which bind to human cyclin A as encoded by the sequence of SEQ ID NO: 1 and which are useful in detecting cellular proliferation. The antibodies of the invention can be polyclonal or monoclonal, and are preferably generated by injection of purified human cyclin A into an animal host. The invention is particularly advantageous because it has been discovered that the gene encoding for human cyclin A is a site for integration of the hepatitis B virus associated with hepatocellular carcinoma, and by detecting human cyclin A through the use of the antibodies of the invention, one can detect and diagnose cell proliferation. Through the use of the present invention, cell proliferation and tumorigenesis can thus be detected at early stages, and such conditions can then be treated or inhibited by the use of anti-sense human cyclin A DNA.
摘要翻译:本发明一般涉及编码人类细胞周期蛋白A的DNA序列,特别是编码抗体或包含此类抗体的抗血清,其结合如SEQ ID NO:1的序列编码的人细胞周期蛋白A并且可用于检测细胞 增殖。 本发明的抗体可以是多克隆的或单克隆的,并且优选通过将纯化的人细胞周期蛋白A注射到动物宿主中来产生。 本发明是特别有利的,因为已经发现编码人细胞周期蛋白A的基因是与肝细胞癌相关的乙型肝炎病毒整合的位点,并且通过使用本发明的抗体检测人细胞周期蛋白A 可以检测和诊断细胞增殖。 通过使用本发明,因此可以在早期阶段检测细胞增殖和肿瘤发生,然后可以通过使用反义人细胞周期蛋白A DNA来治疗或抑制这些病症。
摘要:
The invention is directed generally to a DNA sequence coding for human cyclin A and in particular to antibodies, or antisera including such antibodies, which bind to human cyclin A as encoded by the sequence of SEQ ID NO: 1 and which are useful in detecting cellular proliferation. The antibodies of the invention can be polyclonal or monoclonal, and are preferably generated by injection of purified human cyclin A into an animal host. The invention is particularly advantageous because it has been discovered that the gene encoding for human cyclin A is a site for integration of the hepatitis B virus associated with hepatocellular carcinoma, and by detecting human cyclin A through the use of the antibodies of the invention, one can detect and diagnose cell proliferation. Through the use of the present invention, cell proliferation and tumorigenesis can thus be detected at early stages, and such conditions can then be treated or inhibited by the use of anti-sense human cyclin A DNA.
摘要翻译:本发明一般涉及编码人类细胞周期蛋白A的DNA序列,特别是编码抗体或包含此类抗体的抗血清,其结合如SEQ ID NO:1的序列编码的人细胞周期蛋白A,并且其可用于检测细胞 增殖。 本发明的抗体可以是多克隆的或单克隆的,并且优选通过将纯化的人细胞周期蛋白A注射到动物宿主中来产生。 本发明是特别有利的,因为已经发现编码人细胞周期蛋白A的基因是与肝细胞癌相关的乙型肝炎病毒整合的位点,并且通过使用本发明的抗体检测人细胞周期蛋白A 可以检测和诊断细胞增殖。 通过使用本发明,因此可以在早期阶段检测细胞增殖和肿瘤发生,然后可以通过使用反义人细胞周期蛋白A DNA来治疗或抑制这些病症。
摘要:
This invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytcs, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding that HIP/PAP administration has no adverse effects in mammals. This invention concerns a pharmaceutical composition for stimulating liver regeneration in vivo including after chronic/acute liver failure, comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue (36) and ending at the amino acid residue (175) of sequence SEQ ID No 1, in combination with at least one physiologically acceptable excipient.